By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Threshold Pharmaceuticals, Inc. 

170 Harbor Way
Suite 300
South San Francisco  California  94080-6108  U.S.A.
Phone: 650-474-8200 Fax: 650-474-2529



Company News
Threshold Pharma (THLD) And Merck KGaA (MKGAF.PK), Darmstadt, Germany Agree To Key Terms For The Licensing Back Of All Rights To Evofosfamide To Threshold 1/12/2016 12:32:33 PM
Bay Area Threshold Pharma (THLD) Slashing Two-Thirds of its Workforce After Failed Trials 12/21/2015 6:33:21 AM
Threshold Pharma (THLD) Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints 12/8/2015 1:11:02 PM
Threshold Pharma (THLD) Crumbles as Merck KGaA (MKGAF.PK) Abandons Cancer Drug After Trial Failures 12/7/2015 6:00:29 AM
Threshold Pharma (THLD) Enters Into Definitive Co-Promotion Agreement For Evofosfamide With Merck KGaA (MKGAF.PK), Darmstadt, Germany 11/19/2015 12:35:08 PM
Threshold Pharma (THLD) Extends $550 Million Deal with Merck KGaA (MKGAF.PK) for 50% of Cancer Drug’s U.S. Sales 11/18/2015 5:42:55 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Stifel 2015 Healthcare Conference 11/13/2015 12:44:30 PM
Threshold Pharmaceuticals, Inc. (THLD) Release: Preclinical Studies Find That Tarloxotinib May Overcome Resistance To EGFR Tyrosine Kinase Inhibitors 11/10/2015 1:03:33 PM
Threshold Pharmaceuticals, Inc. (THLD) Announces Preclinical Data On Combination Of Evofosfamide With Immune Checkpoint Inhibitors To Be Presented At The SITC 2015 Meeting 11/4/2015 10:50:46 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports Third Quarter 2015 Financial And Operational Results 11/3/2015 12:46:20 PM